ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study

• Sponsor: Southeast University, China (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT06028451
• Collaborator: (none)
• Enrollment: 550
• Anticipated Duration (Months): 15

Study Details

Study Description

Brief Summary

To assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.

Condition or Disease	Intervention/Treatment	Phase
Invasive Aspergillosis	Other: Record the information data

Detailed Description

To assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 550 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
• Anticipated Study Start Date: Sep 15, 2023
• Anticipated Primary Completion Date: Sep 15, 2024
• Anticipated Study Completion Date: Dec 15, 2024

Arms and Interventions

Arm	Intervention/Treatment
Survivors Critically ill patients with invasive aspergillus infection who survived	Other: Record the information data; Record the information data
Nonsurvivors Critically ill patients with invasive aspergillus infection who not survived	Other: Record the information data; Record the information data

Outcome Measures

Primary Outcome Measures

1. mortality [28 day]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age>18 year-old Diagosed as invasive aspergillus infection

Exclusion Criteria:

• Pregnant

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Southeast University, China

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jingyuan,Xu, Principal Investigator, Southeast University, China
• ClinicalTrials.gov Identifier: NCT06028451
• Other Study ID Numbers: 2023ZDYYLL01
• First Posted: Sep 8, 2023
• Last Update Posted: Sep 8, 2023
• Last Verified: Aug 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Jingyuan,Xu, Principal Investigator, Southeast University, China: invasive aspergillus infection
• Additional relevant MeSH terms: Aspergillosis

Study Results

No Results Posted as of Sep 8, 2023